5 results on '"SOBCZYK, MAŁGORZATA"'
Search Results
2. Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis.
- Author
-
Żuber, Zbigniew, Turowska-Heydel, Dorota, Sobczyk, Małgorzata, Banach-Górnicka, Marta, Rusnak, Katarzyna, Piszczek, Anna, and Mężyk, Elżbieta
- Subjects
- *
JUVENILE idiopathic arthritis , *METHOTREXATE , *SUBCUTANEOUS infusions , *THERAPEUTICS - Abstract
Objectives: Methotrexate (MTX) is one of the most frequently used, highly effective disease-modifying drugs in juvenile idiopathic arthritis (JIA) therapy. The drug can be administered orally or subcutaneously, but the efficacy and tolerance of these two routes of administration raise doubts in JIA patients. The aim of the study was to evaluate MTX efficacy and tolerability after switching from the oral to the subcutaneous route of administration in children with JIA. Material and methods: A single-centre, questionnaire-based assessment of MTX efficacy and tolerance in 126 unselected JIA patients with longer than 6 months of follow-up was performed. In all patients, MTX was initially administered orally. The response to MTX treatment was analysed according to American College of Rheumatology (ACR) paediatric criteria. Results: Six-month MTX therapy was effective (ACR score ≥ 30) in 83 children (65.9%). The oral route of MTX administration was changed to subcutaneous in 32 patients after a mean period of 14 months due to intolerance (n = 20) or reluctance to take the oral formulation (n = 12). This group of children was significantly younger (p = 0.02) but did not differ from the group of children that continued oral treatment in other aspects, including MTX dose. Six months after switching from oral to subcutaneous MTX the ACR score remained unchanged. Three children (9.4%) still reported symptoms of drug intolerance. Conclusions: The switch from oral to subcutaneous MTX may increase the response rate in JIA patients with intolerance of its oral formulation. The reluctance to take oral MTX can be anticipated in early childhood, and should be considered in the individualization of therapy, having also in mind the lower risk of severe gastrointestinal adverse drug reactions. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis.
- Author
-
Żuber, Zbigniew, Turowska-Heydel, Dorota, Sobczyk, Małgorzata, and Chudek, Jerzy
- Subjects
- *
HLA histocompatibility antigens , *JUVENILE idiopathic arthritis , *DISEASE prevalence , *ANTIRHEUMATIC agents , *HORMONE therapy , *ADRENOCORTICAL hormones , *MICROARRAY technology - Abstract
Introduction: Human leukocyte antigen B27 (HLA-B27) is considered as a risk factor for development of juvenile idiopathic arthritis (JIA). The aim of this study was to analyse the prevalence of HLA-B27 antigen in JIA categories and its influence on disease onset and response to conventional therapy. Material and methods: The retrospective analysis included 461 unselected children with JIA hospitalized in a single reference rheumatology centre between July 2007 and June 2012. The diagnosis was based on criteria by the International League of Association for Rheumatology. HLA-B27 was determined in 387 of all patients (84%) by hybridization of the amplified, labelled product to immobilize it on the microarray probe. Results: HLA-B27 antigen was found in 104 of 383 affected children (27.2%), 48 of 206 girls (23.3%), and 56 of 177 boys (31.6%) - most frequently in patients with enthesitis-related arthritis (71%), psoriatic arthritis (50%) and unclassified cases (86.7%). The age of JIA onset was slightly (by 1 year) but significantly different in patients with and without HLA-B27 antigen [11 (8.5-14) vs. 10 (5-13.5) years.; p < 0.001]. The use of disease-modifying antirheumatic drugs (DMARDs) and corticosteroids was more frequently clinically ineffective in HLA-B27 positive than negative patients (23.1% vs. 15.2%; p = 0.09). Patients with polyarthritis, systemic, and psoriatic arthritis more frequently received biological therapy. HLA-B27 positive patients with enthesitis-related arthritis received biological therapy more frequently than HLA-B27 negative ones (20.4% vs. 0, respectively; p = 0.09). Conclusions: HLA-B27 antigen is a strong risk factor for the development of enthesitis-related arthritis, and to a lesser extent for psoriatic arthritis and extended course of oligoarthritis. The presence of this antigen does not affect the disease onset but seems to predict resistance to therapy with disease-modifying drugs and corticosteroids. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Pachydermodactyly - a report of two cases.
- Author
-
Żuber, Zbigniew, Dyduch, Grzegorz, Jaworek, Andrzej, Turowska-Heydel, Dorota, Sobczyk, Małgorzata, Banach-Górnicka, Marta, Rusnak, Katarzyna, and Górecki, Wojciech
- Subjects
- *
HEALTH outcome assessment , *MEN'S health , *RHEUMATOID arthritis , *PATIENTS - Abstract
Pachydermodactyly (PDD) is a rare and benign form of digital soft tissues fibromatosis, which affects the skin of the fingers. The disorder is characterized by asymptomatic, symmetric, progressive soft tissue swelling of the proximal interphalangeal (PIP) joints of the fingers. The etiology of disease remains unknown. It is usually acquired, even though there are some publications that document family cases. It affects mainly adolescent men. We report two boys with the bilateral swelling of the of the PIP joints of the fingers and skin and subcutaneous tissue thickening. Based on clinical manifestations, radiological study and histopathological examination, pachydermodactyly was diagnosed. PDD is a rare and benign disorder, although it is important to consider other diseases, especially rheumatic conditions, in the differential diagnosis in order to avoid unnecessary additional tests and treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Marfan syndrome - typical musculoskeletal abnormalities, rare occurrence in children.
- Author
-
Żuber, Zbigniew, Solakiewicz, Anna, Turowska-Heydel, Dorota, and Sobczyk, Małgorzata
- Subjects
- *
MARFAN syndrome , *GENETIC disorders , *MUSCULOSKELETAL system abnormalities , *AORTA , *TISSUES , *DISEASES - Abstract
Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder. It is caused by a mutation in the fibrillin-1 (FBN1) gene located on chromosome 15 as a result of activation of transforming growth factor ß. Since MFS affects most organs and tissues, patients with this disease constitute a clinically heterogeneous group. Specifically, MFS affects and causes disorders of the musculoskeletal system, eyes, heart and large blood vessels. A poor prognosis is expected due to the high risk of cardiovascular and ocular complications, which are caused by progressive dilatation of the aorta and ectopia lentis. This article describes a case of MFS with typical musculoskeletal abnormalities. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.